AT1 is valued seemingly accurately given the current deals they...

AT1 is valued seemingly accurately given the current deals they have. They don't bring in substantial revenues at this point to justify a higher price point. It also gets pumped and dumped on any news of potential agreements. Without LDX also, AT1 would be solely reliant on 2 main deals, their HIV test with the AUS government and their pregnancy test.

LDX is undervalued based on the current contracts and revenue being brought in. It was sold off the last 12 months since the FDA high which I put down to:

- Profit selling from the FDA approval high.
- Capital Raising at 20% reduction of VWAP to 7c.
- Delay in CLIA waiver
- Lower revenue from product sales in US than people were probably expecting (first launch)
- More recently, tax selling.

People on the ASX are highly impatient and want to see penny stocks pump 40% in a day to make easy money. Some of these stocks get sold off because impatient people have unrealistic time frames on things etc.

I wouldn't say LDX is a trap. Its all dependent on your trading timeframe. If you buy in now, then its reasonable to assume you would see reasonable returns when the price heads back to where it was mid-end last year. Bought in on FDA approval high, then you probably aren't going to see anything for some time.